Stoke Therapeutics Inc STOK:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
Last | 04/22/24 EDT
11.25quote price arrow down-0.80 (-6.64%)
Volume
883,764
52 week range
3.35 - 16.40
Loading...
  • Open0.00
  • Day High0.00
  • Day Low0.00
  • Prev Close11.25
  • 52 Week High16.40
  • 52 Week High Date03/27/24
  • 52 Week Low3.35
  • 52 Week Low Date10/27/23

Key Stats

  • Market Cap579.08M
  • Shares Out51.47M
  • 10 Day Average Volume1.04M
  • Dividend-
  • Dividend Yield-
  • Beta0.79
  • YTD % Change113.88

KEY STATS

  • Open0.00
  • Day High0.00
  • Day Low0.00
  • Prev Close11.25
  • 52 Week High16.40
  • 52 Week High Date03/27/24
  • 52 Week Low3.35
  • 52 Week Low Date10/27/23
  • Market Cap579.08M
  • Shares Out51.47M
  • 10 Day Average Volume1.04M
  • Dividend-
  • Dividend Yield-
  • Beta0.79
  • YTD % Change113.88

RATIOS/PROFITABILITY

  • EPS (TTM)-2.38
  • P/E (TTM)-4.73
  • Fwd P/E (NTM)-4.80
  • EBITDA (TTM)-112.303M
  • ROE (TTM)-60.80%
  • Revenue (TTM)8.781M
  • Gross Margin (TTM)-
  • Net Margin (TTM)-1,192.34%
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date05/02/2024(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Stoke Therapeutics Inc

 

Profile

MORE
Stoke Therapeutics, Inc. is a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with ribonucleic acid (RNA)-based medicines. The Company, through its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO) approach, is engaged in developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its first compound, STK-001, is in clinical testing for the treatment of Dravet...
Seth Harrison M.D.
Independent Chairman of the Board
Edward Kaye M.D.
Chief Executive Officer, Director
Huw Nash Ph.D.
Chief Operating Officer, Chief Business Officer
Stephen Tulipano CPA
Chief Financial Officer
Jonathan Allan
General Counsel, Company Secretary
Address
45 WIGGINS AVENUE
Bedford, MA
01730
United States

Top Peers

SYMBOLLASTCHG%CHG
ABSI
Absci Corp
4.51-0.26-5.45%
VERV
Verve Therapeutics Inc
6.91+0.27+4.07%
ORIC
Oric Pharmaceuticals Inc
8.72-0.47-5.11%
ALXO
ALX Oncology Holdings Inc
14.23-1.37-8.78%
MLYS
Mineralys Therapeutics Inc
11.14-0.15-1.33%